Compare TG Therapeutics Inc (TGTX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while ZIM Integrated Shipping Services Ltd trades at $24.99 (market cap $2.93B). The key difference: TG Therapeutics Inc is far larger — about 2.8× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | ZIM | |
|---|---|---|
Market Cap | $8.26B | $2.93B |
Sector | Health | Industrials |
52-Week High | $59.06 | $29.27 |
52-Week Low | $26.39 | $12.44 |
Enterprise Value | $8.50B | $6.78B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
ZIM trades at $24.31, showing minimal daily movement. The stock faces a bearish technical outlook with mixed earnings, including a Q1 2026 miss. Financially, it maintains a strong cash position and low valuation multiples, but profitability has declined from 2025 to 2026. Recent news is dominated by merger uncertainty with Hapag-Lloyd and leadership changes.
The outlook is cautious due to regulatory risks around the merger and volatile shipping rates. Upside exists if the deal proceeds or freight markets tighten, but downside risk is significant if the merger fails, with analyst targets near $16.75. High cash burn and insider selling add to near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
